key: cord-1021211-b4joa5tx authors: Dai, Wenhao; Zhang, Bing; Jiang, Xia-Ming; Su, Haixia; Li, Jian; Zhao, Yao; Xie, Xiong; Jin, Zhenming; Peng, Jingjing; Liu, Fengjiang; Li, Chunpu; Li, You; Bai, Fang; Wang, Haofeng; Chen, Xi; Cen, Xiaobo; Hu, Shulei; Yang, Xiuna; Wang, Jiang; Liu, Xiang; Xiao, Gengfu; Jiang, Hualiang; Rao, Zihe; Zhang, Lei-Ke; Xu, Yechun; Yang, Haitao; Liu, Hong title: Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease date: 2020-03-28 journal: bioRxiv DOI: 10.1101/2020.03.25.996348 sha: aafe0afc46c28bd52f9cf5a1701d5771a2236aa3 doc_id: 1021211 cord_uid: b4joa5tx SARS-CoV-2 is the etiological agent responsible for the COVID-19 outbreak in Wuhan. Specific antiviral drug are urgently needed to treat COVID-19 infections. The main protease (Mpro) of SARS-CoV-2 is a key CoV enzyme that plays a pivotal role in mediating viral replication and transcription, which makes it an attractive drug target. In an effort to rapidly discover lead compounds targeting Mpro, two compounds (11a and 11b) were designed and synthesized, both of which exhibited excellent inhibitory activity with an IC50 value of 0.05 μM and 0.04 μM respectively. Significantly, both compounds exhibited potent anti-SARS-CoV-2 infection activity in a cell-based assay with an EC50 value of 0.42 μM and 0.33 μM, respectively. The X-ray crystal structures of SARS-CoV-2 Mpro in complex with 11a and 11b were determined at 1.5 Å resolution, respectively. The crystal structures showed that 11a and 11b are covalent inhibitors, the aldehyde groups of which are bound covalently to Cys145 of Mpro. Both compounds showed good PK properties in vivo, and 11a also exhibited low toxicity which is promising drug leads with clinical potential that merits further studies. sequence identify to SARS-CoV 4, 5, 6 . This novel coronavirus was named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses, and the pneumonia was designated as COVID-19 by the World Health Organization (WHO) on February 11, 2020 7 The substrates of coronaviruses 3CL pro (M pro ) show some similarity, and most 3CL protease inhibitors are peptidomimetic covalent inhibitors derived from the natural substrates. The active sites are highly conserved among all CoV M pro and are usually composed of four pockets (S1', S1, S2 and S4) 22, 23 . The thiol of a cysteine residue in the S1' pocket can anchor inhibitors by a covalent linkage, which is important for the inhibitors to maintain anti-viral activity. In our design of new inhibitors, the aldehyde was selected as a new warhead in P1' to occupy the S1'pocket. As the (S)-γ-lactam ring has been proved to be suitable in the S1 pocket of 3C pro and 3CL pro , this ring was expected to be a good choice in P1 of new inhibitors. Furthermore, the S2 pocket of coronavirus 3CL pro is usually large enough to accommodate the bigger P2 fragment. To assess the possibility of π -π stacking interactions and hydrophobic interaction with the S2 pocket, the aryl and cyclohexyl group were placed in P2 (compounds 11a and 11b). Recombinant SARS-CoV-2 M pro (3CL pro ) was expressed and purified from In order to elucidate the mechanism of inhibition of SARS-CoV-2 M pro by 11a, we determined the high-resolution crystal structure of this complex at 1.5-Å resolution (Table S1 ) 18, 26, 27 . The crystals of M pro -11a belongs to the space group C2 and each asymmetric unit contains only one molecule (Table S1) . By a crystallographic 2-fold symmetry axis, two molecules (designated protomer A and protomer B) associate into a homodimer (Figure S2) . The structure of each protomer contains three domains and the substrate-binding site is located in the cleft between domain I and II (Figure S2) . At the active site of SARS-CoV-2 M pro , Cys145 and His41 (Cys-His) form a catalytic dyad ( Figure S2) . Figure 2B ). The cyclohexyl group is also surrounded by the side chains of Met49, Tyr54, Met165 and Asp187, producing extensive hydrophobic interactions ( Figure 2B) . The indole group of 11a at P3 is exposed to solvent (S4 site) and is stabilized by Glu166 through a hydrogen bond (Figure 2B) . The side chains of residues Pro168 and Gln189 interact with the indole group of 11a through hydrophobic interactions. Interestingly, multiple water molecules (named W1-W6) play an important role in binding 11a (Figure 2B ). W1 interacts with the amide bonds of 11a through a hydrogen bond, whereas W2-6 form a number of hydrogen bonds with the aldehyde group of 11a and the residues of Asn142, Gly143, Thr26, Thr25, His41 and Cys44, which contributes to stabilize 11a in the binding pocket ( Figure 2B) . The crystal structure of SARS-CoV-2 M pro in complex with 11b is very similar to that of the 11a complex and shows a similar inhibitor binding mode (Figure 2C, 2D, S3B and S3C) . The difference in binding is probably due to the aryl group of 11b at P2. Compared with the cyclohexyl group in 11a, the aryl group undergoes a significant rotation (Figure 2C) . The side chains of residues His41, Met49, Met165 and Val186 interact with this aryl group through hydrophobic interactions ( Figure 2D ). The side chain of Gln189 stabilizes the aryl group with an additional hydrogen bond ( Figure 2D ). In short, these two crystal structures reveal an identical inhibitory mechanism in that these two compounds occupy the substrate-binding pocket, mimicking the intermediates in the catalytic reaction, which blocks the enzyme activity of SARS-CoV-2 M pro . To further substantiate the enzyme inhibition results, we evaluated the ability of To explore the further druggability of the compounds 11a and 11b, both of two compounds were evaluated for its pharmacokinetic properties. As shown in Those results indicating that compound 11a has good PK properties to warrant further study. In vivo toxicity evaluation of 11a. The in vivo toxicity study (Table S4 ) of 11a have been carried out on SD rats and Beagle dogs. The acute toxicity of 11a was conducted on SD rats, and no SD rats died after receiving 40 mg/kg via intravenous drip administration. When the dosage was raised to 60 mg/kg, one of four SD rats was died. The dose range toxicity study of 11a was conducted for seven days in the dosing level at 2, 6, 18 mg/kg on SD rats and at 10-40 mg/kg on Beagle dogs, once daily dosing (QD), by intravenous drip, all animals were clinically observed once a day at least and no obvious toxicity was observed in each group. The results show 11a with low toxicity on rats and dogs. New infectious agents have emerged to cause epidemics, such as SARS-CoV, showed good PK properties in vivo, and 11a also exhibited low toxicity which is promising compounds for heading to the clinical study. A Novel Coronavirus from Patients with Pneumonia in China Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster A pneumonia outbreak associated with a new coronavirus of probable bat origin A new coronavirus associated with human respiratory disease in China Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet Severe acute respiratory syndrome-related coronavirus: The species and its viruses -a statement of the Coronavirus Study Group Novel Coronavirus(2019-nCoV) Situation Report, 21" World Health Organization First Case of 2019 Novel Coronavirus in the United States Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Can an anti-HIV combination or other existing drugs outwit the new coronavirus Coronaviruses post-SARS: update on replication and pathogenesis Emerging coronaviruses: Genome structure, replication, and pathogenesis Identification of novel subgenomic RNAs and noncanonical transcription initiation signals of severe acute respiratory syndrome coronavirus Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease Structure of coronavirus main proteinase reveals com-bination of a chymotrypsin fold with an extra alpha-helical domain The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor Design of wide-spectrum inhibitors targeting coronavirus main proteases alpha-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment Cyanohydrin as an Anchoring Group for Potent and Selective Inhibitors of Enterovirus 71 3C Protease Production of authentic SARS-CoV M(pro) with enhanced activity: application as a novel tag-cleavage endopeptidase for protein overproduction Phaser crystallographic software We thank Prof. James Halpert and LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript.